• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

CeloNova touts nano-coated stent trial results

November 19, 2020 By Danielle Kirsh

celonovaCeloNova recently announced positive interim results from its randomized trial of Cobra PzF stenting to reduce the duration of triple therapy.

The randomized, global 14-day dual anti-platelet therapy study of high bleeding risk (HBR) patients enrolled 996 HBR participants across 59 enrolling global sites. Each patient received either the Cobra PzF NCF with 14-day dual antiplatelet therapy (DAPT) or an FDA-approved DES with 3 or 6 months DAPT.

“Today marks a very significant milestone in providing valuable clinical insights into the DAPT duration and stent choice for high bleeding risk patients formally excluded from clinical trials,” Robert Byrne, chair of cardiovascular research at the Royal College of Surgeons and principal investigator in the Cobra Reduce trial, said in a news release. “I would like to thank my colleagues for their outstanding support in successfully completing this portion of the study despite challenges brought on by the COVID-19 world pandemic. We look forward to concluding patient follow-up and secondary analysis at 12 months.”

In the trial, 100% of enrolled patients are on oral anticoagulation therapy (OAC) with over 90% of patients presenting with atrial fibrillation. About half of the patients had a second or third major or minor ARC-HBR bleeding criteria like ischemic stroke, cancer, anemia or severe or end-stage chronic kidney disease.

Significantly fewer patients in the Cobra PzF NCS arm received a reduction in OAC intensity compared to the DES group. Both groups presented with highly complex lesions and the Cobra PzF NCS arm presented with statistically higher bifurcation rates.

Interim results also demonstrated numerically similar rates in the composite co-primary endpoint of ischemic safety compared to the DES arm (Cobra: 7.7% vs DES: 5.2%; p=0.061); additional analysis showed statistical non-inferiority when the composite endpoint includes only cardiac-related mortality; equal low probable and definite stent thrombosis in both groups; low initial ischemic-drive TLR at 6 months.

“We are pleased with COBRA PzF NCS’ preliminary performance with just 14-days DAPT in aspects of bleeding and ischemic events,” president and CEO Carl St. Bernard said. “Finding the right DAPT balance is critical to reducing the complexity and complications of long-DAPT regimens following stent placement. The Cobra Reduce study has advanced our understanding of how to best strike this balance.”

“It is encouraging to see that the Cobra stent demonstrated a very low stent thrombosis rate with just 14-days DAPT in this high-risk patient population,” Roxana Mehran, a member of the Cobra Reduce Steering Committee, said. “We hope to gain further insight into its efficacy with 14-days DAPT in the secondary analysis at 12 months.”

CeloNova anticipates final co-primary endpoint analysis and secondary endpoints at 12 months to be revealed in Q2 of 2021.

Filed Under: Research & Development Tagged With: CeloNova

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

Medical Tubing & Extrusion

Subscribe to our e-newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS